Drugs / UCB-1184197
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00726648 | Jul 2008 → Mar 2009 | relapsing-remitting multiple sclerosis | UCB Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00484536 | May 2007 → Nov 2009 | multiple sclerosis | UCB Pharma | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCB-1184197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297363 ↗ |
| Known as | CDP323 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00726648 ↗ |
| Known as | Zaurategrast ethyl ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297363 ↗ |
| Action | Inhibit | “CDP323, an oral α4-integrin inhibitor” PMID 23472197 ↗ Mar 20131“Integrin alpha-4 inhibitor” CHEMBL4297363 ↗ |
| Modality | Small molecule | — CHEMBL4297363 ↗ |
| Route | Oral | “CDP323, an oral α4-integrin inhibitor” PMID 23472197 ↗ Mar 2013 |
| Target | ITGA4 | “Integrin alpha-4 inhibitor” CHEMBL4297363 ↗ |